PMID- 23858325
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130716
LR  - 20220316
IS  - 1756-2856 (Print)
IS  - 1756-2864 (Electronic)
IS  - 1756-2856 (Linking)
VI  - 6
IP  - 4
DP  - 2013 Jul
TI  - Topiramate: Effects on cognition in patients with epilepsy, migraine headache and 
      obesity.
PG  - 211-27
LID - 10.1177/1756285613481257 [doi]
AB  - This paper reviews the clinical implications of topiramate (TPM)-induced 
      cognitive deficits in patients with epilepsy, migraine headache, obesity, and in 
      normal populations, followed by reviews of the literature describing the reversal 
      of such deficits upon medication discontinuation. It also discusses animal 
      investigations of TPM's role of neuroprotection in brain injury. TPM's most 
      intolerable adverse effects (AEs) are on verbal fluency and reaction time, 
      resulting in high discontinuation rates in patients taking it for epilepsy and 
      migraine headache. However, because TPM is so effective in the treatment of 
      epilepsy and migraine headache, its use is expected to continue. There appears to 
      be greater tolerance of TPM's cognitive AEs when it is used in the treatment of 
      obesity, perhaps because of the lower doses required. Research attempting to 
      predict the populations most vulnerable to the cognitive effects caused by TPM is 
      ongoing. Studies suggest that one such population may include patients with a 
      past psychiatric history. Slow titration and administration of the lowest 
      possible doses may decrease risk of cognitive deficits.
FAU - Sommer, Barbara R
AU  - Sommer BR
AD  - Stanford University School of Medicine, Department of Psychiatry, 401 Quarry 
      Road, Stanford, CA 94305-5723, USA.
FAU - Mitchell, Erica L
AU  - Mitchell EL
FAU - Wroolie, Tonita E
AU  - Wroolie TE
LA  - eng
PT  - Journal Article
PL  - England
TA  - Ther Adv Neurol Disord
JT  - Therapeutic advances in neurological disorders
JID - 101480242
PMC - PMC3707352
OTO - NOTNLM
OT  - cognition
OT  - epilepsy
OT  - migraine
OT  - obesity
OT  - psychiatric
OT  - topiramate
COIS- Conflict of interest statement: The authors declare no conflicts of interest in 
      preparing this article.
EDAT- 2013/07/17 06:00
MHDA- 2013/07/17 06:01
PMCR- 2013/07/01
CRDT- 2013/07/17 06:00
PHST- 2013/07/17 06:00 [entrez]
PHST- 2013/07/17 06:00 [pubmed]
PHST- 2013/07/17 06:01 [medline]
PHST- 2013/07/01 00:00 [pmc-release]
AID - 10.1177_1756285613481257 [pii]
AID - 10.1177/1756285613481257 [doi]
PST - ppublish
SO  - Ther Adv Neurol Disord. 2013 Jul;6(4):211-27. doi: 10.1177/1756285613481257.